



## For Health Professionals Who Care For Cancer Patients

### Inside This Issue:

- **Editor's Choice** – New Programs: HIPEC using Cisplatin for Peritoneal Desmoplastic Small Round Cell Tumour (SAHIPEC)
- **Drug Update** – BCCA Auxiliary Label Revised
- **Cancer Drug Manual** – Revised: Irinotecan; Acknowledgment of CDM Contributors
- **Benefit Drug List** – New: SAHIPEC; Revised: LUAVMTNE
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – New: SAHIPEC; Revised: BRAVEVEX, UBRAVLCAP, UBRAVTCAP, BRLAACD, GIGAJCC, GUAJPG, ULKATOATRA, ULKATOP, ULKATOR, LUAVMTNE, ULUAVCRIZ, LUAVPP, ULYIBRU, UMYBORPRE, UMYBORREL, UMYLENDEX, UMYMPBOR
- **Website Resources and Contact Information**

### EDITOR'S CHOICE

#### NEW PROGRAMS

The BCCA Provincial Systemic Therapy Program has approved the following program effective 1 January 2016:

#### Sarcoma:

**Hyperthermic Intraperitoneal Chemotherapy (HIPEC) using Cisplatin for Peritoneal Desmoplastic Small Round Cell Tumour (SAHIPEC)** – Desmoplastic small round cell tumour (DSRCT) is a rare and aggressive soft tissue sarcoma. It commonly presents as multifocal abdominal metastases with a gross appearance similar to carcinomatosis. At the BC Cancer Agency, patients with peritoneal carcinomatosis are currently treated with HIPEC in addition to cytoreductive surgery. The Agency now covers HIPEC in patients with DSRCT based on findings from a retrospective study demonstrating the benefit of HIPEC following complete cytoreduction.<sup>1</sup>


#### References:

1. Hayes-Jordan A, Green HL, Lin H, et al. Complete cytoreduction and HIPEC improves survival in desmoplastic small round cell tumor. Ann Surg Oncol 2014;21:220-224.

## DRUG UPDATE

### BCCA AUXILIARY LABEL REVISED

The medication auxiliary label, “**DO NOT TAKE ANTACIDS WITHIN TWO (2) HOURS OF THIS MEDICINE**”, has been changed to a white background to prevent selection error of labels with a similar design.



Please note that a custom order from the label supplier is now required. The revised label has been updated on the [BCCA Auxiliary Label List](#).

## CANCER DRUG MANUAL

### REVISED MONOGRAPHS AND PATIENT HANDOUTS

#### Irinotecan Monograph:

- *Interactions* table – corrected the mechanism for the St. John’s wort interaction

### ACKNOWLEDGMENT OF CDM CONTRIBUTORS

The Cancer Drug Manual staff would like to acknowledge the contributions of the CDM Editorial Board and the expert reviewers for their ongoing support of the Cancer Drug Manual, and for generously sharing their time and expertise throughout the year.

Editorial Board	Expert Reviewers
<p><u>Physicians:</u> Angela Chan (Medical Oncologist, BCCA) Dave Fenton (Medical Oncologist, BCCA) Deepa Wadhwa (Medical Oncologist, BCCA) Jeff Davis (Pediatric Oncologist, BC Children’s Hospital)</p> <p><u>Nurses:</u> Sylvi Baillie (BCCA-SAHCSI) Fran Topp (BCCA-VCC) Karen Janes (BCCA-VCC)</p> <p><u>Pharmacists:</u> Mandeep Bains (BCCA-VCC) Sanna Pellatt (BCCA-VICC) Roberta Esau (BC Children’s Hospital) Clarissa Cheng (Burnaby Hospital)</p>	<p>Vanessa Bernstein (Medical Oncologist, BCCA) Jackie Buston (Pharmacist, BCCA) Kim Chi (Medical Oncologist, BCCA) Donna Forrest (Hematologist, Leukemia/BMT Program of BC) Linda Hamata (Pharmacist, BCCA) Christian Kollmannsberger (Medical Oncologist, BCCA) John Paul McGhie (Medical Oncologist, BCCA) Judith Nyrose (Pharmacist, BCCA) Kerry Savage (Medical Oncologist, BCCA) Laurie Sehn (Medical Oncologist, BCCA) Christine Simmons (Medical Oncologist, BCCA) Robert Tillmanns (Pharmacist, BCCA)</p>

## BENEFIT DRUG LIST

### NEW PROGRAMS

The following program has been added to the BCCA [Benefit Drug List](#) effective 1 January 2016:

Protocol Title	Protocol Code	Benefit Status
Summary for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Peritoneal Desmoplastic Small Round Cell Tumour (DSRCT) Using <b>CISplatin</b>	SAHIPEC	Class I

### REVISED PROGRAMS

The following program has been revised on the BCCA [Benefit Drug List](#) effective 1 January 2016:

Protocol Title	Protocol Code	Benefit Status
Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) with <b>Erlotinib</b> After First-Line Chemotherapy	LUAVMTNE	Class II (Previously Restricted)

## LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

**BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts** are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring BCCA Compassionate Access Program approval are prefixed with the letter "U".

### NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
SAHIPEC	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Summary for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients with Peritoneal Desmoplastic Small Round Cell Tumour (DSRCT) Using CISplatin

### REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAVEVEX	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dispensing quantity clarified</i>	Therapy for Advanced Breast Cancer Using Everolimus and Exemestane
UBRAVLCAP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Therapy for Metastatic Breast Cancer Using Capecitabine and Lapatinib
UBRAVTCAP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Palliative Therapy for Metastatic Breast Cancer Using Trastuzumab (HERCEPTIN) and Capecitabine

**REVISED PROTOCOLS, PPPOS AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):**

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRLAACD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Onset of hair loss clarified</i>	Treatment of Locally Advanced Breast Cancer Using DOXOrubicin and Cyclophosphamide Followed by DOCEtaxel
GIGAJCC	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Minor typo corrected</i>	Adjuvant Chemotherapy of Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation, Using CISplatin and Capecitabine
GUAJPG	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Minor typo corrected</i>	Adjuvant Therapy for Urothelial Carcinoma Using Cisplatin and Gemcitabine
ULKATOATRA	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose modifications clarified</i>	First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide and Tretinoin
ULKATOP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose modifications clarified</i>	First-Line Induction and Consolidation Therapy of Acute Promyelocytic Leukemia Using Arsenic Trioxide, Tretinoin and DAUNOrubicin
ULKATOR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Dose modifications clarified</i>	Induction and Consolidation Therapy of Relapsed Acute Promyelocytic Leukemia Using Arsenic Trioxide
LUAVMTNE	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Eligibility and protocol code revised</i>	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer with Erlotinib After First-Line Chemotherapy
ULUAVCRIZ	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Second-Line Treatment of ALK-Positive Advanced Non-Small Cell Lung Cancer with Crizotinib
LUAVPP	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	First-Line Treatment of Advanced Non-Small Cell Lung Cancer with Platinum and Pemetrexed
ULYIBRU	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Dispensing quantity clarified</i>	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using Ibrutinib
UMYBORPRE	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Amyloidosis added to Eligibility, new references added</i>	Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone With or Without Cyclophosphamide as Induction Pre-Stem Cell Transplant
UMYBORREL	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Amyloidosis added to Eligibility, new references added</i>	Treatment of Relapsed Multiple Myeloma Using Bortezomib, Dexamethasone With or Without Cyclophosphamide
UMYLENEX	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Minor typo corrected</i>	Therapy of Multiple Myeloma Using Lenalidomide with Dexamethasone

**REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):**

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
UMYMPBOR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Amyloidosis added to Eligibility, new references added</i>	Treatment of Multiple Myeloma using Melphalan, predniSONE and Weekly Bortezomib With the Option of Substituting Cyclophosphamide for Melphalan

## WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	<a href="http://www.bccancer.bc.ca">www.bccancer.bc.ca</a>
Systemic Therapy Update	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update">www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update</a>
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy">www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy</a>
Cancer Drug Manual	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual">www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual</a>
Cancer Management Guidelines	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines">www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines</a>
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols">www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols</a>
Systemic Therapy Program Policies	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy">www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy</a>
CON Pharmacy Educators	<a href="http://www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy">www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy</a>

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Nursing Professional Practice	604-877-6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250-712-3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604-851-4710 Toll Free 877-547-3777		
BCCA-Centre for the North	250-645-7300 Toll Free 888-775-7300		
BCCA-Fraser Valley Centre	604-930-2098 Toll Free 800-523-2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250-712-3900 Toll Free 888-563-7773		
BCCA-Vancouver Centre	604-877-6000 Toll Free 800-663-3333		
BCCA-Vancouver Island Centre	250-519-5500 Toll Free 800-670-3322		

## EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)  
 Mário de Lemos, PharmD, MSc (Oncol)  
 Caroline Lohrisch, MD  
 Robert Crisp, BScPT, MBA

Beth Morrison, MLS  
 Ava Hatcher, RN BN CONc  
 Rob Watt, BSc(Pharm)